Read by QxMD icon Read

Bone Metastases Prostate cancer

Rakesh K Pathak, Uttara Basu, Anis Ahmad, Shrita Sarkar, Anil Kumar, Bapurao Surnar, Saba Ansari, Katarzyna Wilczek, Michael E Ivan, Brian Marples, Nagesh Kolishetti, Shanta Dhar
Multimodal therapies are used to treat advanced cancers including castration-resistant prostate cancer to manage the biological characteristics of the tumors like inflammation, bone metastases, and participation of metabolically altered cancer stem cells (CSCs) that have integral roles in disease dissemination and progression. We developed a multifunctional polymer-based self-assembled technology to deliver a predefined stoichiometric combination of a chemotherapy and an anti-inflammatory agent in a stimuli responsive manner, to complement and improve the currently established treatment methods of prostate cancer...
December 2018: Biomaterials
Matias Riihimäki, Hauke Thomsen, Kristina Sundquist, Jan Sundquist, Kari Hemminki
Population-based data on metastatic patterns are lacking because cancer registries seldom record metastases. This study uses a novel population-based approach to identify metastases and describes metastatic pathways from 14 common primary cancers to 12 specific metastatic sites. A total of 179 581 patients with metastatic cancer were identified from the Swedish Cancer Registry and metastatic sites were identified using the Cause of Death Register and the National Patient Register. Patterns of metastatic spread were described across age and sex...
October 16, 2018: Cancer Medicine
Ulka Vaishampayan, Izabela Podgorski, Lance K Heilbrun, Jawana M Lawhorn-Crews, Kimberlee C Dobson, Julie L Boerner, Karri Stark, Daryn Smith, Elisabeth I Heath, Joseph Fontana, Anthony F Shields
BACKGROUND: Cabozantinib is a multitargeted tyrosine kinase inhibitor demonstrating remarkable responses in prostate cancer bone metastases . We studied the dynamics of biomarker changes with imaging, and biopsies pre- and post-therapy to explore factors that are likely to be predictive of efficacy with cabozantinib. METHODS: Eligibility included metastatic castrate resistant prostate cancer patients with normal organ function and performance status 0-2. Cabozantinib 60 mg orally was administered daily...
October 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Haider Mussawy, Lennart Viezens, Malte Schroeder, Svenja Hettenhausen, Jördis Sündermann, Jasmin Wellbrock, Kai Kossow, Christian Schaefer
BACKGROUND: Prostate cancer-related morbidity is associated with its preferential spread to the bone. Although the molecular interactions between the bone microenvironment and cancer cells have been researched extensively, the relevance of the microvascular properties of prostate cancer bone metastases remains largely unknown. Most preclinical studies focusing on microvascular analyses are based on heterotopic tumor implantation, whereas the impact of the microenvironment on site-specific growth behavior and angiogenesis is rarely addressed...
October 16, 2018: BMC Cancer
Christopher Parker, Valerie Lewington, Neal Shore, Clemens Kratochwil, Moshe Levy, Ola Lindén, Walter Noordzij, Jae Park, Fred Saad
Importance: Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types. Observations: Theoretically, the high-energy emission of short-range alpha particles causes complex double-stranded DNA breaks, eliciting cell death. No known resistance mechanism to alpha particles has been reported or scientifically established. The short-range emission of alpha particle radiation confines its cytotoxic effect to cancerous lesions and the surrounding tumor microenvironment while limiting toxic effects to noncancerous tissues...
September 20, 2018: JAMA Oncology
Ana Loizaga-Iriarte, Isabel Camargo Ibargarai, Nerea Senarriaga-Ruiz de la Illa, Isabel Lacasa-Viscasillas, Miguel Unda-Urzaiz
OBJECTIVE: To analyze the available evidence on Radium 223 therapy, an alfa particle emitter with specific action on bone metastases, studied on patients with castration resistant prostate cancer. EVIDENCE ACQUISITION: We review the pivotal study ALSYMPCA, that served to get the drug approval for this phase of the disease, and the new data obtained from its use. We also performed a search of ongoing studies with Radium 223 alone or in combination with other molecules...
September 2018: Archivos Españoles de Urología
Pedro Isaacsson Velho, Fahad Qazi, Sayeedul Hassan, Michael A Carducci, Samuel R Denmeade, Mark C Markowski, Daniel L Thorek, Theodore L DeWeese, Daniel Y Song, Phuoc T Tran, Mario A Eisenberger, Emmanuel S Antonarakis
BACKGROUND: Pathogenic mutations in genes mediating homologous recombination (HR) DNA repair are present in 20-30% of men with metastatic castrate-resistant prostate cancer (mCRPC). Radium-223 is a bone-seeking α-emitter that induces double-strand DNA breaks, thereby killing cancer cells in the bone microenvironment. OBJECTIVE: To evaluate the potential impact of germline or somatic HR-deficiency (HRD) mutations on radium-223 efficacy in mCRPC with bone metastasis...
October 4, 2018: European Urology
Haley D Axelrod, Kenneth C Valkenburg, Sarah R Amend, Jessica L Hicks, Princy Parsana, Gonzalo Torga, Angelo M De Marzo, Kenneth J Pienta
Prostate cancer bone metastasis remains lethal and incurable, and often arises years after elimination of the primary tumor. It is unclear what underlies the decades-long clinical latency before recurrence, but evidence points to the existence of dormant residual tumor cells that disseminated before the primary tumor was eliminated. To design therapies to prevent progression of disseminated tumor cells (DTCs) into lethal metastases, it is crucial to understand the mechanism(s) underlying this dormancy. The current study functionally validated our previous observation that implicated the GAS6/AXL axis in mediating DTC dormancy in the bone marrow...
October 5, 2018: Molecular Cancer Research: MCR
Ali Erhan Kayalar, Eylem Eren Eyupoglu, Seda Akyildiz, Askin Esen Hasturk, Abdurrahman Bakir
Calvarial and dural metastases of papillary thyroid carcinomas (PTC) are rarely reported in the medical literature. Most frequent calvarial metastases are seen to originate from lung, breast, and prostate cancers. Thyroid cancer metastases are generally well vascularized and cause destruction in the bone tissues. First choice of treatment in distant metastases of PTC is surgery and radioactive iodine treatment for the primary cause. Postsurgical radiotherapy is used in accepted and suitable patients.
October 2018: Journal of Craniofacial Surgery
Karine Briot, Julien Paccou, Philippe Beuzeboc, Jacques Bonneterre, Béatrice Bouvard, Cyrille B Confavreux, Catherine Cormier, Bernard Cortet, Jean-Michel Hannoun-Lévi, Christophe Hennequin, Rose-Marie Javier, Eric Lespessailles, Didier Mayeur, Pierre Mongiat Artus, Marie-Hélène Vieillard, Françoise Debiais
Androgen-deprivation therapy (ADT) in patients with prostate cancer can be achieved surgically or chemically, notably by prescribing LHRH analogs. Major bone loss occurs rapidly in both cases, due to the decrease in testosterone levels, and can increase the fracture risk. The objective of developing these recommendations was to achieve a practical consensus among various scientific societies, based on a literature review, about osteoporosis prevention and treatment in patients on ADT. The following scientific societies contributed to the work: Société Française de Rhumatologie (SFR), Groupe de Recherche et d'Information sur les Ostéoporoses (GRIO), Groupe Européen d'Etudes des Métastases Osseuses (GEMO), Association Francophone pour les SOins de Support (AFSOS), Association Française d'Urologie (AFU), Société Française de Radiothérapie Oncologique (SFRO)...
October 1, 2018: Joint, Bone, Spine: Revue du Rhumatisme
Paulina Nastały, Martyna Filipska, Colm Morrissey, Elke Eltze, Axel Semjonow, Burkhard Brandt, Klaus Pantel, Natalia Bednarz-Knoll
Aldehyde dehydrogenase 1 (ALDH1) characterizes tumor-initiating cells in solid tumors; however, little is known about its expression in intratumoral stromal cells. Herein, we aimed to dissect its potential dual relevance in prostate cancer (PCa). ALDH1 expression was evaluated immunohistochemically in tumor and stromal cells in primary PCa and metastases. It was correlated to clinico-pathologic parameters, patients' outcome, and selected proteins (CK5/6, CK14, CK8/18, CK19, EpCAM, Ki-67, E-cadherin, N-cadherin, and vimentin)...
September 12, 2018: Translational Research: the Journal of Laboratory and Clinical Medicine
Timothy Uzoma Mbaeri, Jideofor Chukwuma Orakwe, Ogochukwu I Ezejiofor
Prostate cancer remains the most common noncutaneous cancer in men, especially in this era of prostate-specific antigen assay. Prostate cancer metastases have been known to commonly affect the lymphatics, bones, and lungs. Prostate cancer metastasis to the skin is very rare (<1%) and often signifies a terminal disease. Involvement of the skin has been thought to be through lymphatic spread by embolization or permeation, hematogenous spread, and implantation during surgery (port site in radical prostatectomy)...
July 2018: Nigerian Journal of Surgery: Official Publication of the Nigerian Surgical Research Society
Nurhan Ergül, Burçak Yilmaz Güneş, Uğur Yücetaş, Mahmut Gökhan Toktaş, Tevfik Fikret Çermik
INTRODUCTION: Prostate-specific membrane antigen (PSMA) ligand PET/CT is an emerging modality to detect the metastatic disease, especially in intermediate- and high-risk prostate cancer (PCa). In this study, we analyzed the contribution of Ga-PSMA-11 PET/CT in staging and therapy management of newly diagnosed PCa. MATERIALS AND METHODS: A total of 78 patients with biopsy-proven PCa who were referred for Ga-PSMA-11 PET/CT for primary staging were retrospectively analyzed...
September 28, 2018: Clinical Nuclear Medicine
Simon Gauvin, Alexis Rompré-Brodeur, Guillaume Chaussé, Maurice Anidjar, Franck Bladou, Stephan Probst
INTRODUCTION: We sought to evaluate the diagnostic performance of 18F-fluorocholine positron emission tomography-computed tomography (18F-FCH PET/CT) for initial staging of patients with high-risk prostate cancer. Secondary objectives were to compare the value of 18F-FCH PET/CT to conventional imaging modalities and to evaluate its clinical impact. METHODS: We conducted a retrospective study including 76 patients who underwent 18F-FCH PET/CT for initial staging of high-risk prostate cancer...
September 27, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Asim Afaq, Jamshed Bomanji
Introduction: There is an unmet clinical need for early, accurate imaging of recurrent prostate cancer to improve patient outcomes. Staging, by conventional bone scintigraphy and CT have become outdated. 68Ga-PSMA PET/CT imaging in this setting has developed rapidly, with widespread International adoption in line with evidence-based guidelines in this group of patients. Sources of data: A PubMed search of English language articles was performed using following keywords: PSMA, PET/CT, biochemical recurrence, prostate cancer...
September 29, 2018: British Medical Bulletin
Toshiyuki Tsurumoto, Tetsuaki Wakebe, Keiko Ogami-Takamura, Keishi Okamoto, Kazunori Tashiro, Kazunobu Saiki
A human skeleton of a middle-aged adult male was found in a 5th-6th century Kinoue-Kodo stone coffin excavated from the southwest marginal region of the Oita plains, northeast Kyushu, Japan. The skeleton was buried respectfully in the ancient tomb, and red pigment was applied to his face after death. We report herein findings from computed tomography imaging of the skeleton and discuss the multiple osteoblastic lesions identified in the humerus, scapula, clavicle, vertebra, pelvic bones, and skull of this individual...
2018: BioMed Research International
Igor Tsaur, Isabel Heidegger, Alexander Kretschmer, Hendrik Borgmann, Cristian Mirvald, Giorgio Gandaglia, Alberto Briganti, Roderick van den Bergh, Derya Tilki, Piet Ost, Guillaume Ploussard, Cristian Surcel
Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities...
September 26, 2018: Urologic Oncology
Liselotte M S Boevé, Maarten C C M Hulshof, André N Vis, Aeilko H Zwinderman, Jos W R Twisk, Wim P J Witjes, Karl P J Delaere, R Jeroen A van Moorselaar, Paul C M S Verhagen, George van Andel
BACKGROUND: The cornerstone of standard treatment for patients with primary bone metastatic prostate cancer (mPCa) is androgen deprivation therapy (ADT). Retrospective studies suggest a survival benefit for treatment of the primary prostatic tumour in mPCa, but to date, no randomised-controlled-trials (RCTs) have been published addressing this issue. OBJECTIVE: To determine whether overall survival is prolonged by adding local treatment of the primary prostatic tumour with external beam radiation therapy (EBRT) to ADT...
September 25, 2018: European Urology
Tomonori Kato, Satoko Kojima, Ayumi Fujimoto, Kotaro Otsuka, Takahito Suyama, Kyokushin Hou, Kazuhiro Araki, Hiroshi Masuda, Kazuto Yamazaki, Akira Komiya, Yukio Naya
A 69-year-old man presented initially with back pain and incomplete bilateral lower limb paralysis. The level of prostate-specific antigen (PSA) in the patient was elevated to 167.0 ng/ml, and multiple bone metastases were detected. Thoracic laminectomy was performed in an emergency due to spinal decompression. Subsequently, the patient was diagnosed with prostate cancer from an examination of resected bone specimens. Combined androgen blockade with degarelix and bicalutamide was initiated in October 2013. Consequently, the serum PSA level decreased to <1...
October 2018: Oncology Letters
Mingxiong Sheng, Lingling Wan, Changming Liu, Chunxiao Liu
INTRODUCTION: This study aims to assess whether cryosurgery is a feasible local therapy for bone metastatic prostate cancer (bmPCa). METHODS: A total of 23 patients with bmPCa who received cryosurgery and adjuvant androgen deprivation therapy (ADT) were included in the cryosurgery group (Group 1). Another 23 matched patients who received only ADT served as the control (Group 2). Prostate specific antigen (PSA) nadir level, time to PSA nadir, time to castration-resistant prostate cancer (CRPC), progression-free survival and therapy response of bone metastases were compared between the groups...
September 24, 2018: Singapore Medical Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"